

1 **Mitral Annular Disjunction in Heritable Thoracic Aortic Disease: Insights From the Montalcino**
2 **Aortic Consortium**

3 Short Title: MAD in Thoracic Aortic Disease

4 Total Word Count: 2380

5 Kishan L. Asokan; Kishan.L.Asokan@uth.tmc.edu; University of Texas Health Science Center at
6 Houston, Houston, TX, USA

7 Jennifer R. Landes; Jennifer.R.Landes@uth.tmc.edu; University of Texas Health Science Center at
8 Houston, Houston, TX, USA

9 Wannes Renders, MD; Wannes.Renders@ugent.be; Ghent University, Ghent, Belgium

10 Laura Muiño Mosquera, MD, PhD; laura.muinomosquera@uzgent.be; Ghent University Hospital, Ghent,
11 Belgium

12 Julie De Backer, MD, PhD; julie.debacker@ugent.be; Ghent University Hospital, Ghent, Belgium

13 David W Jantzen, MD; tjantzen@childrensnebraska.org; University of Nebraska Medical Center, Omaha,
14 NE, USA

15 Anji T. Yetman, MD; ayetman@childrensnebraska.org; University of Nebraska Medical Center, Omaha,
16 NE, USA

17 Gisela Teixido-Tura, MD, PhD; gisela.teixido@vallhebron.cat; University Hospital Vall d'Hebron,
18 Barcelona, Spain

19 Arturo Evangelista, MD; arturevangelistamasip@gmail.com; University Hospital Vall d'Hebron,
20 Barcelona, Spain

21 Richmond Jeremy, MB.BS, PhD; richmond.jeremy@sydney.edu.au; University of Sydney, Sydney,
22 Australia

23 Edward G. Jones, MD; edward.jones@bcm.edu; Texas Children's Hospital, Houston, TX, USA

24 Shaine Morris, MD, MPH; shainem@bcm.edu; Texas Children's Hospital, Houston, TX, USA

25 Tam Doan; MD; Tam.Doan@bcm.edu; Texas Children's Hospital, Houston, TX, USA

26 Maral Ouzonian; MD, PhD; maral.ouzounian@uhn.ca; University of Toronto, Toronto, Canada

27 Alan Braverman; MD; abraverm@wustl.edu; Washington University School of Medicine, St Louis, MO,
28 USA

29 Guillaume Jondeau; MD, PhD; guillaume.jondeau@aphp.fr; Hospital Bichat-Claude Bernard, Paris,
30 France

31 Olivier Milleron, MD; olivier.milleron@aphp.fr; Hospital Bichat-Claude Bernard, Paris, France

32 Siddharth K. Prakash, MD, PhD; Siddharth.K.Prakash@uth.tmc.edu; University of Texas Health Science
33 Center at Houston, Houston, TX, USA

34 Dianna M. Milewicz, MD, PhD; Dianna.M.Milewicz@uth.tmc.edu; University of Texas Health Science
35 Center at Houston, Houston, TX, USA

36

37 Corresponding Author:

38 Siddharth K. Prakash, MD, PhD

39 Department of Internal Medicine

40 John P and Kathrine G McGovern Medical School

41 University of Texas Health Science Center at Houston

42 6431 Fannin Street

43 MSB 6.116

44 Houston, Texas 77030 USA

45 Siddharth.K.Prakash@uth.tmc.edu

46 **Abstract**

47 Background: Mitral annular disjunction (MAD), posterior displacement of the mitral valve leaflet hinge
48 point, predisposes to arrhythmias or sudden cardiac death. We evaluated the burden of MAD, mitral valve
49 prolapse (MVP), and mitral regurgitation (MR) by heritable thoracic aortic disease (HTAD) gene in a
50 cross-sectional analysis of 2014-2023 data in the Montalcino Aortic Consortium (MAC) registry.

51 Methods: MAD was determined by direct measurement of echocardiographic images. MR and MVP were
52 defined according to current clinical guidelines. Associations were evaluated using chi-squared or Fisher
53 exact tests.

54 Results: MR and MVP were enriched in MAC participants (672) with pathogenic variants (PV) in TGF- β
55 pathway genes. The combination of MR and MVP was associated with mitral surgery and arrhythmias. In
56 the subgroup with available images, MAD was enriched in *SMAD3* PV compared to other TGF- β PV (PR
57 1.8 [1.1-2.8], $P < 0.02$). Severe disjunction (>10 mm) was only observed in the TGF- β subgroup and was
58 further enriched in participants with *SMAD3* PV (PR 3.1 [1.1-8.6]). MVP (PR 5.2 [3.0-9.0]) and MR (PR
59 2.7 [1.8-3.9]) were increased in participants with MAD, but MAD was not independently associated with
60 adverse cardiac or aortic events.

61 Conclusions: Mitral phenotypes are more prevalent in individuals with PV in TGF- β pathway genes,
62 particularly *SMAD3*, and are associated with adverse aortic and cardiac events. Because congenital mitral
63 disease may be the primary presenting feature of *SMAD3* PV, genetic testing for HTAD should
64 be considered for such individuals, especially if they also have a family history of HTAD.

65 **Indexing terms:** Thoracic aortic aneurysms and dissections, congenital heart disease, mitral valve, Loeys-
66 Dietz syndrome, cardiovascular genetics

67

68 **Nonstandard Abbreviations and Acronyms**

69 LDS Loeys-Dietz syndrome

70 MAD Mitral Annular Disjunction

71 MFS Marfan syndrome

72 SCD Sudden Cardiac Death

73 HTAD Heritable Thoracic Aortic Disease

74 TGF- β Transforming Growth Factor-Beta

75

76 **Clinical/Research Perspective**

77 *What Is New?*

78 1) Mitral regurgitation, mitral valve prolapse, and mitral annular disjunction (MAD) are common in
79 heritable thoracic aortic disease (HTAD) caused by pathogenic variants (PV) in TGF- β pathway genes
80 (*SMAD3*, *TGFBR1*, *TGFBR2*, *TGFB2*, or *TGFB3*) and are associated with adverse cardiac events.

81 2) Pathological mitral phenotypes are particularly prominent in people with *SMAD3* PV and may be the
82 presenting feature of HTAD in some cases.

83 *What Are the Clinical Implications?*

84 3) Pathological mitral valve phenotypes may identify a high-risk subgroup of HTAD cases with more
85 frequent adverse cardiovascular events. Because congenital mitral disease may be the primary presenting
86 feature of *SMAD3* PV, genetic testing for HTAD should be considered for such individuals, especially if
87 they also have a family history of HTAD.

88

89 Introduction

90 Mitral annular disjunction (MAD) is atrial displacement of the mitral valve leaflet hinge point
91 from the ventricular myocardium. MAD was first described in autopsy studies of individuals with mitral
92 valve prolapse (MVP) who experienced sudden cardiac death (SCD) [1, 2]. MVP or MAD may pose an
93 increased risk for ventricular arrhythmias and SCD, and MAD is an independent risk factor for arrhythmic
94 events [2-8]. Cardiac magnetic resonance studies identified myocardial fibrosis in the inferolateral left
95 ventricle of MAD cases and implicated significant fibrosis as a nidus for ventricular arrhythmias [6]. In
96 Marfan syndrome (MFS), MAD also predisposes to ventricular tachycardia and SCD, and displacement of
97 the mitral hinge point > 10 mm is correlated with the likelihood of ventricular arrhythmias [4, 9]. The
98 genetic cause of most sporadic MAD cases and potential associations between pathogenic variants (PV) in
99 other HTAD genes and MAD are unknown.

100 The Montalcino Aortic Consortium (MAC, NCT04005976) is an international collaboration of
101 expert HTAD clinical centers that was established in 2013 to investigate the disease course of individuals
102 with validated PV in a clinically actionable HTAD gene [10, 11]. Genetic syndromes (e.g. Marfan
103 syndrome or Loeys-Dietz syndrome) cause approximately 5% of HTAD cases, with the vast majority
104 classified as non-syndromic [12]. Known causative HTAD genes encode extracellular matrix proteins
105 (*FBNI*, *COL3A1*, *LOX*), components of the TGF- β signaling pathway (*SMAD2*, *SMAD3*, *SMAD4*, *TGFB2*,
106 *TGFB3*, *TGFBRI*, *TGFB2R*), and smooth muscle cell contractile components (*ACTA2*, *MYLK*, *PRKG1*,
107 *MYH11*). [12,13][16]. More than 20% of individuals with non-syndromic HTAD have a family history of
108 HTAD, signaling the urgent need for early diagnosis and surveillance of affected individuals [13, 14]. The
109 MAC data on the natural history of HTAD due to specific PV have informed new clinical
110 recommendations for management of HTAD based on the underlying mutated gene in the 2022
111 ACC/AHA Guidelines for the Diagnosis and Management of Aortic Disease [13, 17]. The specific type of
112 PV may influence the timing of elective surgery to prevent an aortic dissection because some PV are
113 associated with dissections at smaller absolute aortic diameters.

114 Aneurysms and dissections of smaller arteries and congenital cardiac malformations such as
115 bicuspid aortic valve and septal defects are more common in some HTAD PV carriers [18][19][20]. We
116 hypothesize that mitral valve prolapse (MVP), mitral regurgitation (MR), or MAD may be enriched in
117 groups with HTAD PV due to phenotypic overlap between MAD, MFS, and HTAD. This study focused
118 on the analysis of mitral phenotypes including MAD in the MAC cohort and potential associations with
119 the mutated HTAD gene.

120

121 **Methods**

122 We conducted a multicenter cross-sectional study of MAC registry participants. The study protocol
123 was reviewed and approved by the Committee for the Protection of Human Subjects at the University of
124 Texas Health Science Center at Houston (IRB HSC-MS-16-0191). The investigators accessed person-
125 level data from a single registry to create the study population. Additional data or clarifications were
126 requested from the enrolling site investigators as needed. The data collection period was from 12/2014 to
127 8/2023. We considered pathogenic and likely pathogenic variants as a single group for analysis (referred
128 to as PV). Participants without validated HTAD gene PV were excluded from the analysis. We also
129 excluded individuals with *FBNI* PV because MAC exclusively enrolled pediatric *FBNI* cases at the time
130 of this analysis.

131 The primary independent variable was mitral disease, defined as any degree of mitral valve
132 prolapse (MVP), or mild, moderate, or severe mitral regurgitation (MR). The primary dependent variables
133 were clinical outcomes: the diagnosis of any arrhythmia, congestive heart failure (CHF), or aortic
134 dissection, or aortic or mitral valve surgery. The principal covariates were sex and the HTAD PV. For the
135 subgroup of MAC participants with available images, the primary independent variable was MAD.

136 MAD distance was measured by direct review of echocardiogram images. We determined that
137 MAD was present if we measured at least three millimeters between the posterior mitral valve leaflet
138 hinge point and the inferolateral myocardium using the inner edge to inner edge method [5]. MAD was

139 measured during mid-systole at the peak of the T wave in the parasternal long axis view. Two experienced
140 reviewers reported the mean of three measurements for each cine series.

141 Parasternal long axis images were rated using American Society of Echocardiography criteria for
142 orientation and image quality. Orientation was acceptable if the horizontal septum deviated less than 30
143 degrees from the horizontal plane, the proximal aorta aortic and mitral valves were visible, and the
144 ventricular septum was visible to the apex. Image quality was assessed by brightness level, resolution, and
145 focus on the region of interest. Reviewers rated each category as optimal, adequate, or inadequate. If any
146 category was inadequate, the image was excluded from analysis.

147 Pearson's chi-squared tests or Fisher exact tests were used for comparisons of categorical data.
148 Quantitative data were described using median values with interquartile ranges. The strength of
149 associations was assessed by calculating the E-values of prevalence ratios (PR) [21]. A multivariate
150 regression model was constructed to evaluate associations between age, sex, mutation type, MAD, MVP,
151 and MR and the composite outcome of aortic surgery, mitral surgery, aortic dissection, arrhythmia, or
152 CHF using DATAtab (DATAtab e.U. Graz, Austria).

153

154 **Results**

155 From an initial sample of 1080 MAC participants, 130 subjects were excluded due to missing
156 genotypes. 203 participants were excluded due to missing MR or MVP phenotypes, and 75 were excluded
157 for missing variant pathogenicity classifications. A total of 672 MAC participants (51% male, median age
158 36 years [IQR 19,51]) were included in this study: 312 (46%) had PV in TGF- β pathway genes. Images
159 from 240 participants were used to assess MAD (50% male, median age 33 years [IQR 20,33]). Nine
160 subjects were excluded from the MAD sub-study due to image quality. Three quarters of MAC
161 participants had a PV in an HTAD gene (Table 1). Participants with variants of uncertain significance
162 (n=155) were excluded from this analysis.

163

164 Mitral Valve Disease in the MAC Cohort

165 The prevalence of MR and MVP in the United States Population is estimated at 2-3% [23, 24]. In
166 the MAC cohort, the overall prevalence of MR was 22%, the prevalence of moderate or severe MR was
167 3%, and the prevalence of MVP was 14% (Table 1). Therefore, MR and MVP are 5-10 times more
168 prevalent in MAC than in the general population. There were no significant differences in the prevalence
169 of MR or MVP in males vs. females, or in individuals with PV compared to individuals with VUS (Figure
170 S1 and Figure S2).

171 Most individuals with MVP had PV in TGF- β pathway genes (Table 2). Individuals with *SMAD3*,
172 *TGFBR1*, *TGFBR2*, *TGFB2*, or *TGFB3* PV comprised 60% of the MAC cohort with PV but 90% of MVP
173 and 71% of MR cases (Figure S3). The number of MAC participants with *ACTA2* and *TGFBR2* PV were
174 similar, but MVP was seven times more common in the subgroup with *TGFBR2* PV compared to the
175 subgroup with *ACTA2* PV (17/83 (20%) vs. 3/89 (3%), PR 6.1 [1.8-20], $P<0.001$).

176 The proportion of individuals with MVP or mild, moderate, or severe MR was significantly
177 enriched in *TGFBR1* and *SMAD3* PV carriers (Figure S3 and Figure S4). The prevalence of MR was more
178 evenly distributed between groups with PV in other HTAD genes such as *ACTA2* (18%, Table 2).

179 Cardiac outcomes of MAC participants with mitral disease were significantly worse than the
180 outcomes of participants who did not have MVP or MR. Mitral valve surgery (4/32 (13%) vs.
181 2/367 (0.5%), PR 23 [4.4-120], $P<0.001$) and arrhythmias (6/32 (19%) vs. 13/367 (4%), PR 5.3
182 [2.2-13], $P<0.01$) were significantly increased in the group of MAC participants with MVP and MR when
183 compared to the group without MVP or MR (Table 3).

184 The prevalence of moderate or severe MR was not significantly different in MAC participants with
185 PV in TGF- β pathway genes compared to PV in other HTAD genes ($P<0.06$). Individuals with moderate
186 or severe MR more frequently had aortic surgery ($P<0.01$), mitral surgery ($P<0.001$), CHF ($P<0.001$),
187 and arrhythmias ($P<0.01$, Table S2). In the subgroup of participants with available images, the composite
188 of MAD, MVP, and moderate or severe MR was more prevalent in participants with *SMAD3* PV

189 compared to those with PV in other HTAD genes (34/67 (51%) vs. 41/172 (24%), PR 2.1 [1.5-3.0],
190 $P<0.001$).

191 The proportions of probands and relatives who had MVP or MAD were not significantly different,
192 but more probands exhibited the composite clinical endpoint. These findings suggest that the presentation
193 of mitral valve disease was similar in probands and relatives (Table S3).

194

195 Mitral annular disjunction in the MAC cohort

196 Most mitral images were from individuals with PV in TGF- β pathway genes (68%), consistent
197 with the proportion of the TGF- β subgroup in the entire MAC cohort. MAD was observed in 24%
198 (57/240) of the subgroup with available images (Table 4). MAD was more prevalent in MAC participants
199 with PV in TGF- β pathway genes compared to participants with other PV (52/162 (32%) vs. 5/78 (6%),
200 PR 5.0 [2.1-12], $P<0.001$, Figure 1). MAD was highly enriched in MAC participants with *SMAD3* PV
201 compared to PV in other TGF- β pathway genes (29/67 (43%) vs. 23/95 (24%), PR 1.8 [1.1-2.8], $P<0.02$).
202 MAD, MVP, and/or MR was more prevalent in participants with *SMAD3* PV compared to participants
203 with PV in other TGF- β genes (42/67 (63%) vs. 56/95 (41%), PR 1.5 [1.1-2.1], $P<0.02$). MAD was also
204 enriched in MAC participants with PV in *TGFBR1*, *TGFBR2*, and *TGFB2* (Figure S5). The overall
205 prevalence of MAD was not significantly different in males (23%, 27/120) compared to females (25%,
206 30/118, $P<0.7$) or in probands compared to relatives (Table S3).

207 The prevalence of MVP (26/57 (46%) vs. 16/183 (9%), PR 5.2 [3.0-9.0], $P<0.001$) and any degree
208 of MR (30/57 (53%) vs 36/182 (20%), PR 2.7 [1.8-3.9], $P<0.001$), but not moderate or severe MR (8/183
209 (4%) vs. 4/57 (7%), $P<0.3$), was increased in MAC participants who had MAD. However, in a logistic
210 regression model with age, sex, MR, MVP, and PV type, MAD was not independently associated with
211 arrhythmia, aortic surgery, aortic dissection, or CHF in the entire MAC cohort or in participants with
212 *SMAD3* PV (Figure S6). Left ventricular ejection fraction, left atrial volume, and the maximum diameter
213 of the thoracic aorta also did not vary significantly based on the presence of MAD (Table 5).

214 The distance between the annulus and myocardial border was measured in 56 MAC participants,
215 who were categorized as having mild (3-10 mm, 39) or severe (≥ 10 mm, 16) disjunction. Severe
216 disjunction was only observed in MAC participants with TGF- β gene PV and was particularly enriched in
217 the subgroup with *SMAD3* PV (11/67 (16%) vs. 5/95 (5%), PR 3.1 [1.1-8.6], $P < 0.03$). Pathological mitral
218 phenotypes (>mild MR, severe disjunction, or MAD with MVP) without significant aortic dilation ($Z < 3$)
219 were present only in MAC participants with PV in TGF- β pathway genes, were enriched in the subgroup
220 with *SMAD3* PV (12/67 (18%) vs. 3/95 (3%), PR 5.7 [1.7-19], $P < 0.01$, Table S4), and were significantly
221 more prevalent in relatives compared to probands (Table S3). There was no significant difference in the
222 prevalence of severe annular disjunction between males and females (7/120 (6%) vs. 9/118 (8%)).

223

224 Discussion

225 In MAC participants with HTAD, we found that the prevalence of MVP was five times higher than
226 in the general population and was frequently accompanied by MAD [23, 24]. Our data is consistent with
227 other studies showing that PV in TGF- β pathway genes, primarily *TGFBR1* (22%, 11/50), *TGFBR2* (20%,
228 17/83), *TGFB3* (25%, 5/20), and *SMAD3* (20%, 16/80), are most strongly associated with these mitral
229 phenotypes [4,25,26,31]. The overall rates of MVP and MAD were 7-8 times higher in MAC participants
230 with PV in TGF- β pathway genes than in the rest of the MAC cohort. TGF- β dysregulation can increase
231 matrix metalloproteinase activity and activate endothelial to mesenchymal transition in valve interstitial
232 cells, predisposing to myxomatous mitral valve degeneration [27]. We also identified MAD in MAC
233 participants who did not have PV in TGF- β pathway genes, primarily the subgroup with *ACTA2* PV [13].
234 These data show how the pathophysiology caused by PV in HTAD genes may extend beyond the aorta
235 and highlight potential implications for PV carriers who are at increased risk for cardiac complications
236 related to MVP, such as arrhythmias or CHF.

237 We observed that mitral phenotypes in MAC are significantly associated with aortic surgery,
238 mitral surgery, and arrhythmias. It is unclear if mitral and aortic disease are causally linked, or if

239 pathological mitral disease with MAD may reflect more severe connective tissue degeneration that
240 predisposes to HTAD or myocardial fibrosis driving arrhythmias [28, 29, 31, 32]. The subgroup of MAC
241 participants with MVP and MR appear to be at particularly high risk for adverse cardiac events. Our data
242 indicate that this group may benefit from more intensive surveillance or targeted interventions [29, 30].

243 In contrast to MAD in MFS, we found that MAD was not independently associated with aortic or
244 cardiac events in MAC participants. This is likely because most MAC participants with MAD also
245 presented with MVP. In MFS, the arrhythmic risk that was attributed to MAD occurred predominately in
246 the context of other mitral phenotypes, with arrhythmias detectable in 40% of individuals who had MVP
247 and MAD compared to 20% of individuals with MVP and no MAD [8, 33]. In this study, the rate of
248 arrhythmias in MAC participants who had both MAD and MVP (4/26, 15%) was similar to individuals
249 who had MAD but no MVP (4/31, 13%). However, these observations do confirm that the risk for
250 arrhythmias is markedly increased in the subgroup of individuals with HTAD who have pathological
251 mitral phenotypes and suggest that ambulatory electrocardiographic screening may be beneficial.

252 Biases due to possible misclassification of individuals with mild mitral phenotypes and missing
253 phenotypic data may have caused the effect sizes of associations between mitral and clinical phenotypes to
254 be underestimated. Conversely, we acknowledge that the strength of some associations may be inflated by
255 unmeasured confounders because a relatively limited set of phenotypes were available for study
256 participants. In some cases, combined confounding from these factors could reach the magnitude of the E-
257 value and could nullify a significant association. MAC study sites are referral centers that tend to recruit
258 participants with more severe HTAD phenotypes than in community settings. Therefore, larger
259 prospective studies are needed to corroborate these findings and to determine the prognostic significance
260 of MAD in different genetic and clinical contexts.

261

262 **Acknowledgements**

263 We thank the study participants and referring clinicians without whom this study would not have

264 been possible. Special thanks to Kristin Ankoma-Sey and Walter Velasco-Torrez for assistance with MAC
265 registry data. The Montalcino Aortic Consortium investigators are: Dianna M. Milewicz, MD, PhD; Reed
266 Pyeritz, MD, PhD; Julie De Backer, MD, PhD; Catherine Boileau, PhD; Guillaume Jondeau, MD, PhD;
267 Alan Braverman, MD; Shaine A. Morris, MD; Arturo Evangelista, MD; Maral Ouzounian, MD, PhD;
268 Anji Yetman, MD; Richmond, Jeremy, MB, BS, PhD; Sherene Shalhub, MD, MPH; Eloisa Arbustini,
269 MD; Lesley Ades, MD; Nanette Alvarez, MD; Anne Child MD; Bo Carlberg, MD, PhD; Ismail El-
270 Hamamsy, MD, PhD; David Chitayat, MD; Anne De Paepe, MD, PhD; Richard B. Devereaux, MD;
271 Bridgete Fernandez, MD; Josephine Grima, PhD; Maarten Groenink, MD, PhD; Gabrielle Horne, MD,
272 PhD; Yskert von Kodolitsch, MD; Ronald Lacro, MD; Scott A. LeMaire, MD; Alex V. Levin, MD; David
273 Liang, MD, PhD; Irene Maumenee, MD; Vivienne McConnell; Rocio Moran, MD; Hiroko Morisaki, MD,
274 PhD; Takayuki Morisaki, MD, PhD; Alex Pitcher, PhD; Nancy Poirier, MD; Francesco Ramirez, PhD;
275 Peter Robinson, MD; Dieter Reinhardt, PhD; Meike Rybczynski, MD; George Sandor, MD; Lynn Sakai,
276 PhD; Denver Sallee, MD; Michael N. Singh, MD; Bert Callewaert, MD, PhD; Ellen Regalado, CGC;
277 Marion A. Hofmann-Bowman, MD, PhD; Fabien Labombarda, MD; Laurence Faivre, MD, PhD; Claire
278 Bouleti, MD, PhD; Marjolijn Renard, PhD; Derek Human, BA, BM. BCh; Zoltan Szabolcs, MD, PhD;
279 Andrew Michael Crean, MD; Joseph Bavaria, MD; Apostolos Psychogios, MD; Vidyasagar Kalahasti,
280 MD; Philip Giampietro, MD, PhD; Laura Muiño- Mosquera, MD; Gisela Teixido-Tura, MD, PhD; Olivier
281 Milleron, MD; Mark Evan Lindsay, MD, PhD; Juan Manuel Bowen, MD; Shuping Ge, MD; Anthony
282 Caffarelli, MD; Jolien Roos- Hesselink, MD; Mary B. Sheppard, MD; Andrew Choong, MBBS; Enid
283 Neptune, MD; Zhou Zhou, MD, PhD; Alessandro Pini, MD; Germano Melissano, MD; Elisabetta M.
284 Mariucci, MD; Elena Cervi, MD, PhD; Melissa L. Russo, MD; Pascal-Nicolas Bernatchez, PhD; Mitra
285 Esfandiarei, PhD; Julien Marcadier, MD; Seda Tierney, MD; Jessica Wang, MD, PhD; Kevin Michael
286 Harris, MD; Sara B. MacKay, CCGC; Andrea L. Rideout, CCGC; Sandhya Prakash, MD; Anthony Martin
287 Vandersteen, PhD; Nadine Hanna, PharmD, PhD; Carine Le Goff, PhD; Quentin Pellenc, MD; Patrick
288 Sips, PhD; Scott Michael Damrauer, MD; Lois Starr, MD, PhD; Bo Yang, MD, PhD; Jay B. Shah, MD;

289 Justin T Tretter, MD; Irman Forghani, MD; Kelly Cox, MD; Siddharth K. Prakash, MD, PhD; Sachiko
290 Kanki, MD, PhD; Justin A Weigand, MD; Taylor A. Beecroft, CGC; Alan Frederick Rope, MD; Yaso
291 Emmanuel, MBChB, DPhil.; David Dichek, MD; Michelle Keir, MD; Klaus Kallenbach, MD; Talha Niaz,
292 MBBS; Mirela Tuzovic, MD; Anthony L. Estrera, MD; Timothy Carter, MD; Martin Czerny, MD; Anna
293 Sabaté Rotés, MD, PhD; Brett Carroll, MD; William T. Brinkman, MD; David R. Murdock, MD;
294 Christopher Phillips Jordan, MD.

295

296 **Sources of Funding**

297 DM Milewicz and SK Prakash are funded by the Genetic Aortic Disorders Association (GADA) and
298 the John Ritter Foundation for Aortic Health. DM Milewicz is also funded by the Temerty Family
299 Foundation.

300

301 **Disclosures**

302 The authors have no disclosures to report.

303

304 **Supplemental Material**

305 See Tables S1-S4 and Figures S1-S6.

306 **References**

- 307 1. Hutchins, G.M., G.W. Moore, and D.K. Skoog, *The association of floppy mitral valve with*
308 *disjunction of the mitral annulus fibrosus*. N Engl J Med, 1986. **314**(9): p. 535-540.
309 10.1056/nejm198602273140902
- 310 2. Yeerken, M., et al., *Arrhythmic mitral annular disjunction syndrome: An underestimated cause of*
311 *sudden cardiac death*. Int J Cardiol, 2022. **369**: p. 19-20. 10.1016/j.ijcard.2022.08.006
- 312 3. Essayagh, B., et al., *Presentation and Outcome of Arrhythmic Mitral Valve Prolapse*. J Am Coll
313 Cardiol, 2020. **76**(6): p. 637-649. 10.1016/j.jacc.2020.06.029
- 314 4. Demolder, A., et al., *Association of Mitral Annular Disjunction With Cardiovascular Outcomes*
315 *Among Patients With Marfan Syndrome*. JAMA Cardiol, 2021. **6**(10): p. 1177-1186.
316 10.1001/jamacardio.2021.2312
- 317 5. Dejgaard, L.A., et al., *The Mitral Annulus Disjunction Arrhythmic Syndrome*. J Am Coll Cardiol,
318 2018. **72**(14): p. 1600-1609. 10.1016/j.jacc.2018.07.070
- 319 6. Perazzolo Marra, M., et al., *Morphofunctional Abnormalities of Mitral Annulus and Arrhythmic*
320 *Mitral Valve Prolapse*. Circ Cardiovasc Imaging, 2016. **9**(8): p. e005030.
321 10.1161/circimaging.116.005030
- 322 7. Carmo, P., et al., *Mitral annular disjunction in myxomatous mitral valve disease: a relevant*
323 *abnormality recognizable by transthoracic echocardiography*. Cardiovasc Ultrasound, 2010. **8**: p.
324 53. 10.1186/1476-7120-8-53
- 325 8. Bennett, S., et al., *Definition, prevalence, and clinical significance of mitral annular disjunction in*
326 *different patient cohorts: A systematic review*. Echocardiography, 2022. **39**(3): p. 514-523.
327 10.1111/echo.15299
- 328 9. Comber, D.A., et al., *Arrhythmic Mitral Valve Prolapse and Mitral Annulus Disjunction in*
329 *Heritable Aortic Disease*. CJC Open, 2021. **3**(11): p. 1396-1399. 10.1016/j.cjco.2021.06.013
- 330 10. Regalado, E.S., et al., *Comparative Risks of Initial Aortic Events Associated With Genetic*
331 *Thoracic Aortic Disease*. J Am Coll Cardiol, 2022. **80**(9): p. 857-869. 10.1016/j.jacc.2022.05.054
- 332 11. Murad, A.M., et al., *Spontaneous coronary artery dissection is infrequent in individuals with*
333 *heritable thoracic aortic disease despite partially shared genetic susceptibility*. Am J Med Genet
334 A, 2022. **188**(5): p. 1448-1456. 10.1002/ajmg.a.62661
- 335 12. Caruana, M., et al., *HTAD patient pathway: Strategy for diagnostic work-up of patients and*
336 *families with (suspected) heritable thoracic aortic diseases (HTAD) a statement from the HTAD*
337 *working group of VASCERN*. Eur J Med Genet, 2022: p.104673. 10.1016/j.ejmg.2022.104673
- 338 13. Regalado, E.S., et al., *Comparative Risks of Initial Aortic Events Associated With Genetic*
339 *Thoracic Aortic Disease*. Journal of the American College of Cardiology, 2022. **80**(9): p. 857-869.
340 10.1016/j.jacc.2022.05.054
- 341 14. Biddinger, A., et al., *Familial thoracic aortic dilatations and dissections: a case control study*. J
342 Vasc Surg, 1997. **25**(3): p. 506-11. 10.1016/s0741-5214(97)70261-1
- 343 15. Hiratzka, L.F., et al., *2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for*
344 *the Diagnosis and Management of Patients With Thoracic Aortic Disease*. Journal of the
345 American College of Cardiology, 2010. **55**(14): p. e27-e129. 10.1016/j.jacc.2010.02.015
- 346 16. *FLNA filamin A [Homo sapiens (human)]*. National Library of Medicine 2022 6 November 2022.
347 <https://www.ncbi.nlm.nih.gov/gene/2316>
- 348 17. Kaw, A., et al., *Expanding ACTA2 genotypes with corresponding phenotypes overlapping with*
349 *smooth muscle dysfunction syndrome*. Am J Med Genet A, 2022. **188**(8): p. 2389-2396.
350 10.1002/ajmg.a.62775
- 351 18. Jondeau, G., et al., *International Registry of Patients Carrying TGFBR1 or TGFBR2 Mutations*.
352 Circulation: Cardiovascular Genetics, 2016. **9**(6): p. 548-558.
353 10.1161/CIRCGENETICS.116.001485

- 354 19. Guo, D.C., et al., *LOX Mutations Predispose to Thoracic Aortic Aneurysms and Dissections*. Circ
355 Res, 2016. **118**(6): p. 928-34.10.1161/circresaha.115.307130
- 356 20. Wallace, S.E., et al., *MYLK pathogenic variants aortic disease presentation, pregnancy risk, and*
357 *characterization of pathogenic missense variants*. Genet Med, 2019. 21(1): p. 144-151.
358 10.1038/s41436-018-0038-0
- 359 21. VanderWeele TJ, Ding P. *Sensitivity Analysis in Observational Research: Introducing the E-*
360 *Value*. Ann Intern Med. 2017;167(4):268-274. 10.7326/M16-2607
- 361 22. Mantegazza, V., et al., *Multimodality imaging assessment of mitral annular disjunction in mitral*
362 *valve prolapse*. Heart, 2021. **107**(1): p. 25-32. 10.1136/heartjnl-2020-317330
- 363 23. Douedi, S. and H. Douedi, *Mitral Regurgitation*, in *StatPearls*. 2023, StatPearls Publishing LLC.:
364 Treasure Island (FL).
- 365 24. Shah, S.N., M.K. Gangwani, and T.I. Oliver, *Mitral Valve Prolapse*, in *StatPearls*. 2023,
366 StatPearls Publishing LLC.: Treasure Island (FL).
- 367 25. Gouda, P., et al., *Clinical features and complications of Loeys-Dietz syndrome: A systematic*
368 *review*. Int J Cardiol, 2022. **362**: p. 158-167. 10.1016/j.ijcard.2022.05.065
- 369 26. Delwarde, C., et al., *Genetics and pathophysiology of mitral valve prolapse*. Front Cardiovasc
370 Med, 2023. **10**: p. 1077788. 10.3389/fcvm.2023.1077788
- 371 27. Tang, Q., et al., *The Role of Transforming Growth Factor- β Signaling in Myxomatous Mitral*
372 *Valve Degeneration*. Front Cardiovasc Med, 2022. **9**: p. 872288.10.3389/fcvm.2022.872288
- 373 28. Crestanello, J.A., *Mitral Valve Surgery for Congestive Heart Failure*. Heart Fail Clin, 2018. **14**(4):
374 p. 585-600. 10.1016/j.hfc.2018.06.006
- 375 29. Wheeler, J.B., J.S. Ikonomidis, and J.A. Jones, *Connective tissue disorders and cardiovascular*
376 *complications: the indomitable role of transforming growth factor-beta signaling*. Adv Exp Med
377 Biol, 2014. **802**: p. 107-27. 10.1007/978-94-007-7893-1_8
- 378 30. Hostetler, E.M., et al., *SMAD3 pathogenic variants: risk for thoracic aortic disease and*
379 *associated complications from the Montalcino Aortic Consortium*. J Med Genet, 2019. **56**(4): p.
380 252-260. 10.1136/jmedgenet-2018-105583
- 381 31. Chivulescu, M., et al., *Mitral annulus disjunction is associated with adverse outcome in Marfan*
382 *and Loeys-Dietz syndromes*. Eur Heart J Cardiovasc Imaging, 2021. **22**(9): p. 1035-1044.
383 10.1093/ehjci/jeaa324
- 384 32. Eriksson, M.J., et al., *Mitral annular disjunction in advanced myxomatous mitral valve disease:*
385 *echocardiographic detection and surgical correction*. J Am Soc Echocardiogr, 2005. **18**(10): p.
386 1014-22. 10.1016/j.echo.2005.06.013
- 387 33. van Wijngaarden, A.L., et al., *Parameters associated with ventricular arrhythmias in mitral valve*
388 *prolapse with significant regurgitation*. Heart, 2021. **107**(5): p. 411-418 10.1136/heartjnl-2020-
389 317451
- 390
- 391

392 **Tables**

393

394 **Table 1. Characteristics of Study Cohort (n=672)**

Characteristic	Value	Missing
Female (%)	329 (49)	0
Height, cm (IQR)	173 (163,183)	64
Weight, Kg (IQR)	74 (58,93)	57
Average age at enrollment, y (IQR)	36 (19,51)	4
Mitral valve prolapse (%)	99 (15)	0
Mitral regurgitation (%)	149 (22)	0
Mitral images available (%)	240 (36)	432
Pathogenic or likely pathogenic variants (%)	517 (77)	0
Variants of uncertain significance (%)	155 (23)	0
TGF- β pathway variants (%)	443 (66)	0

395 cm: centimeters, kg: kilograms, y: years, IQR: interquartile range; Missing: number of MAC participants
396 with missing data.

397

398 **Table 2. Mitral Valve Prolapse and Mitral Regurgitation by Gene**

Gene	Cohort	Mitral Valve Prolapse			Mitral Regurgitation		
	n (%)	n (%)	PR (CI)	E (LB)	n (%)	PR (CI)	E (LB)
<i>TGFBR1</i>	50 (10)	11 (22)	1.6 (0.9-2.9)	2.6 (1.0)	16 (32)	1.5 (1.0-2.3)	2.4 (1.0)
<i>TGFBR2</i>	83 (16)	17 (20)	1.5 (1.0-2.5)	2.4 (1.0)	16 (19)	0.9 (0.6-1.4)	1.5 (1.0)
<i>TGFB2</i>	77 (15)	12 (16)	1.2 (0.7-2.1)	1.7 (1.0)	13 (17)	0.8 (0.5-1.3)	1.8 (1.0)
<i>TGFB3</i>	20 (4)	5 (25)	1.9 (0.8-4.1)	3.2 (1.0)	4 (20)	0.9 (0.4-2.3)	1.5 (1.0)
<i>SMAD3</i>	80 (15)	16 (20)	1.5 (0.9-2.4)	2.4 (1.0)	29 (36)	1.7 (1.2-2.3)	2.8 (1.7)
<i>ACTA2</i>	89 (17)	3 (3)	0.3 (0.1-0.8)	6.1 (1.8)	16 (18)	0.8 (0.5-1.3)	1.8 (1.0)
<i>COL3A1</i>	62 (12)	1 (2)	0.1 (0.02-0.9)	19 (1.5)	6 (10)	0.4 (0.2-1.0)	4.4 (1.0)
<i>FLNA</i>	13 (1)	2 (15)	1.2 (0.3-4.2)	1.7 (1.0)	5 (38)	1.8 (0.9-3.6)	3.0 (1.0)
<i>MFAP5</i>	2 (0)	1 (50)	3.7 (0.9-15)	6.9 (1)	1 (50)	2.3 (0.6-9.3)	4.0 (1.0)
<i>SMAD6</i>	1 (0)	1 (100)	7.5 (6.0-9.3)	15 (12)	1 (100)	4.6 (3.9-5.4)	8.7 (7.3)
<i>MYLK</i>	12 (2)	0 (0)	NA	NA	2 (17)	0.8 (0.2-2.8)	1.8 (1.0)
<i>MYH11</i>	6 (1)	0 (0)	NA	NA	1 (17)	0.8 (0.1-4.6)	1.8 (1.0)
<i>PRKG1</i>	10 (3)	0 (0)	NA	NA	1 (10)	0.5 (0.1-3.0)	3.4 (1.0)
<i>LOX</i>	6 (1)	0 (0)	NA	NA	1 (17)	0.8 (0.1-4.6)	1.8 (1.0)
<i>SLC2A10</i>	5 (1)	0 (0)	NA	NA	0 (0)	NA	NA
<i>SMAD2</i>	1 (0)	0 (0)	NA	NA	0 (0)	NA	NA

399 n: number of cases, %: percentage of cohort, Mitral valve prolapse: any degree of mitral valve prolapse,
400 Mitral regurgitation: mild, moderate, or severe mitral regurgitation, PR: prevalence ratio, E: E-value, CI:
401 confidence interval, LB: lower bound. The total prevalence of MVP was 69/517 (13%). The total
402 prevalence of MR was 112/517 (22%). The prevalence of mitral regurgitation was significantly increased
403 in MAC participants with *SMAD3* and *SMAD6* PV.

404 **Table 3. Cardiac and Aortic Events by Mitral Phenotype**

Events	No MR or MVP (%)	MR and MVP (%)	n (%)	PR (CI)	E (LB)
Aortic surgery	105 (29)	14 (44)	175 (34)	1.5 (1.0-2.3)	2.4 (1.0)
Aortic dissection	88 (24)	9 (28)	145 (28)	1.2 (0.7-2.1)	1.7 (1.0)
Mitral valve surgery	2 (0.5)	4 (13)	12 (2)	23 (4.4-120)	45 (8.3)
CHF	10 (3)	1 (3)	22 (4)	1.1 (0.2-8.9)	1.4 (1.0)
Arrhythmia	13 (4)	6 (19)	30 (6)	5.3 (2.1-13)	10 (3.6)

405 MR: mild, moderate, or severe mitral regurgitation, MVP: any degree of mitral valve prolapse, CHF:
406 congestive heart failure, PR: prevalence ratio, E: E-value, CI: 95% confidence interval, LB: lower bound
407 Percentages are in parentheses. Two-tailed *P*-values were calculated using Fischer's exact test. See Table
408 S1 for complete outcomes data. Mitral valve surgery and arrhythmia were increased in MAC participants
409 with MR and MVP.

410 **Table 4. Prevalence of MAD by Gene in MAC Participants with Available Images**

Gene	n (%)	MAD (%)
<i>TGFBR1</i>	22 (9)	6 (27)
<i>TGFBR2</i>	45 (19)	12 (27)
<i>TGFB2</i>	22 (9)	5 (23)
<i>TGFB3</i>	5 (2)	0 (0)
<i>SMAD3</i>	67 (28)	29 (43)
<i>SMAD6</i>	1 (0)	0 (0)
<i>ACTA2</i>	29 (12)	3 (10)
<i>COL3A1</i>	26 (11)	0 (0)
<i>LOX</i>	5 (2)	0 (0)
<i>MFAP5</i>	2 (1)	1 (50)
<i>MYH11</i>	3 (1)	1 (33)
<i>MYLK</i>	1 (0)	0 (0)
<i>PRKG1</i>	2 (1)	0 (0)
<i>FLNA</i>	8 (3)	0 (0)
<i>SCL2A10</i>	2 (1)	0 (0)
TGF- β PV	162 (68)	52 (32)
Other PV	78 (32)	5 (6)
Total	240	57 (24)

411 n: number of cases, %: percentage of cohort. TGF- β : *TGFBR1*, *TGFBR2*, *TGFB2*, *TGFB3*, *SMAD3*,
412 *SMAD6*; MAD: Mitral annular disjunction.


413

414 **Table 5. Characteristics of MAC Participants by MAD Phenotype**

	n	No MAD (n=183)	MAD (n=57)	<i>P</i>
Age	238	35 (20,49) ¹	33 (21,52)	0.66
MVP	240	16 (9)	26 (46)	<0.001
MR	240	36 (20)	30 (53)	<0.001
Arrhythmia	235	20 (11)	8 (14)	0.64
Aortic surgery	239	63 (35)	23 (40)	0.53
Aortic dissection	240	37 (20)	11 (19)	1
Mitral surgery	240	6 (3)	3 (5)	0.69
CHF	186	13 (9)	4 (8)	1
LVEF (%)	153	62 (57,65)	62 (57,65)	0.80
LA Volume (mL)	94	50 (34,69)	54 (36,75)	0.33
Max diameter (mm)	164	38±10 ²	39±7	0.55

415 ¹ Median (Quartile 1, quartile 3) ² Mean±SD. The individual characteristics of all MAC participants with
416 MAD are listed in Table S4. MVP: Any degree of mitral valve prolapse, MR: mild, moderate, or severe
417 mitral regurgitation, CHF: congestive heart failure, LVEF: left ventricular ejection fraction, LA: Left
418 atrium.
419


420 **Figures with Figure Legends**



421
422
423
424
425

Figure 1. Prevalence of MAD in MAC participants with PV in TGF- β pathway genes compared to other HTAD genes. MAD: Mitral annular disjunction. TGF- β pathway genes are *SKI*, *SMAD3*, *SMAD6*, *TGFBRI*, *TGFBRI2*, *TGFB2*, and *TGFB3*.


426 **Supplemental Material**



427
428
429
430
431

Figure S1. Prevalence of mitral valve prolapse and mitral regurgitation in MAC by variant classification. All: all variants, P/LP: pathogenic and likely pathogenic variants, VUS: variants of uncertain significance, MVP: Any degree of mitral valve prolapse, MR: mild, moderate, or severe mitral regurgitation.


432



433
434
435
436

Figure S2. Prevalence of mitral valve prolapse and mitral regurgitation in MAC by sex. Mild, moderate, or severe mitral regurgitation was included in the analysis.


437



438
439
440
441
442
443

Figure S3 Prevalence of mitral valve prolapse and proportion of MAC participants with PV in each HTAD gene. MVP: any degree of mitral valve prolapse, %: percent cases. The prevalence of MVP was significantly enriched in MAC participants with PV in *TGFB1* and *TGFB3*. *MFAP5*, *SMAD2*, and *SMAD6* were excluded due to <5 total cases.

444



445
446
447
448
449

Figure S4. Prevalence of mitral regurgitation and proportion of MAC participants with PV in each HTAD gene. MR: mild, moderate, or severe mitral regurgitation. The prevalence of MR was significantly greater than expected for *TGFBR1*. *MFAP5*, *SMAD2*, and *SMAD6* were excluded due to <5 total cases.

450

Events	Total (%)	MVP (%)	MR (%)	MVP and MR (%)	No MVP or MR (%)
Aortic Surgery	175 (34)	26 (38)	57 (51)*	14 (44)	105 (29)
Aortic Dissection	145 (28)	18 (26)	48 (43)*	9 (28)	88 (24)
Mitral Surgery	12 (2)	7 (10)*	7 (6)*	4 (13)*	2 (0.5)
CHF	22 (4)	2 (3)	10 (9)*	1 (3)	10 (3)
Arrhythmia	30 (6)	11 (16)*	12 (11)*	6 (19)*	13 (4)

451 **Table S1. Cardiac and aortic events stratified by mitral phenotypes.** MVP: any degree of mitral valve prolapse,
452 MR: mild, moderate, or severe mitral regurgitation, CHF: congestive heart failure. Asterisk: $P < 0.05$ vs. 'No MVP
453 or MR' group.
454

455

Events	No MR (%)	Moderate or Severe MR (%)	PR (CI)	E (LB)	<i>P</i>
Aortic Surgery	165 (33)	10 (67)	2.0 (1.4-3.0)	3.4 (2.1)	0.01
Aortic Dissection	138 (27)	7 (47)	1.7 (1.0-3.0)	2.8 (1.0)	0.14
Mitral Surgery	8 (2)	4 (27)	17 (5.7-50)	34 (11)	<0.001
CHF	7 (1)	5 (33)	24 (8.6-70)	48 (17)	<0.001
Arrhythmia	26 (5)	4 (27)	5.1 (2.1-13)	9.7 (3.6)	0.008

456 **Table S2. Cardiac and aortic events of MAC participants with moderate or severe MR.** MR: moderate or
457 severe mitral regurgitation, CHF: congestive heart failure, PR: prevalence ratio, E: E-value, CI: 95% confidence
458 interval, LB: Lower bound. Percentages are in parentheses. Two-tailed *P*-values were calculated using Fisher's
459 exact test.
460

461

Endpoint	Probands (n=243, %)	Relatives (n=185, %)	PR (CI)	E (LB)	P
MR	59 (24)	23 (12)	2.0 (1.3-3.0)	3.4 (1.9)	0.003
MVP	36 (15)	21 (11)	1.3 (0.8-2.2)	1.9 (1.0)	0.32
MAD*	22 (23)	7 (14)	1.7 (0.8-3.6)	2.8 (1.0)	0.27
Pathological Mitral Phenotypes Without Aortic Dilation*	5 (5)	10 (20)	0.3 (0.1-0.7)	20 (6.1)	0.009
Aortic Surgery	103 (42)	38 (21)	2.1 (1.5-2.8)	3.6 (2.4)	< 0.001
Aortic Dissection	90 (37)	35 (19)	2.0 (1.4-2.8)	3.4 (2.1)	< 0.001
Mitral Surgery	7 (3)	2 (1)	2.7 (0.6-13)	4.8 (1.0)	0.31
CHF	6 (2)	4 (2)	1.1 (0.3-4.0)	1.4 (1.0)	1
Arrhythmia	9 (4)	10 (5)	0.7 (0.3-1.7)	2.2 (1.0)	0.48

462

463

464

465

466

467

Table S3. Characteristics of MAC participants by proband status. MR: mild, moderate, or severe mitral regurgitation, MVP: any degree of mitral valve prolapse, MAD: mitral annular disjunction, CHF: congestive heart failure, PR: prevalence ratio, E: E-value, CI: 95% confidence interval, LB: Lower bound. *Analysis was confined to MAC probands (n = 95) and relatives (n = 50) with available images. Aortic dilation: Z-score > 3, Pathological mitral phenotypes: >mild MR, ≥ 10 mm MAD, or MAD with MVP. MR, aortic surgery, and aortic dissection were more prevalent in probands, while predominant mitral phenotypes were more prevalent in relatives.


468

Gene	n (%)	Aortic Dilation (%)	Pathological Mitral Phenotypes (%)	Pathological Mitral Phenotypes without Aortic Dilation (%)
<i>TGFBR1</i>	22 (9)	11 (50)	6 (27)	2 (9)
<i>TGFBR2</i>	45 (19)	18 (40)	10 (22)	1 (2)
<i>TGFB2</i>	22 (9)	3 (14)	4 (18)	0 (0)
<i>TGFB3</i>	5 (2)	2 (4)	0 (0)	0 (0)
<i>SMAD3</i>	67 (28)	10 (15)	17 (25)	12 (18)
<i>SMAD6</i>	1 (0)	1 (100)	0 (0)	0 (0)
<i>ACTA2</i>	29 (12)	10 (35)	2 (7)	0 (0)
<i>COL3A1</i>	26 (11)	3 (12)	0 (0)	0 (0)
<i>LOX</i>	5 (2)	3 (60)	0 (0)	0 (0)
<i>MFAP5</i>	2 (1)	0 (0)	0 (0)	0 (0)
<i>MYH11</i>	3 (1)	2 (67)	0 (0)	0 (0)
<i>MYLK</i>	1 (0)	0 (0)	0 (0)	0 (0)
<i>PRKG1</i>	2 (1)	1 (50)	0 (0)	0 (0)
<i>FLNA</i>	8 (3)	0 (0)	0 (0)	0 (0)
<i>SCL2A10</i>	2 (1)	0 (0)	0 (0)	0 (0)

469
470
471

Table S4. Proportion of MAC participants with pathological mitral phenotypes and/or aortic dilation by HTAD gene. Aortic dilation: Z-score > 3, Pathological mitral phenotypes: >mild MR, ≥ 10 mm MAD, or MAD with MVP. Analysis was limited to the subset of MAC participants with available images (n = 240).

472



473

474

475

476

477

Figure S5. Prevalence of MAD and proportion of MAC participants with PV in each HTAD gene. MAD: mitral annular disjunction. The prevalence of MAD was significantly enriched in MAC participants with PV in *TGFBR1*, *TGFB2*, and *SMAD3*. *MFAP5*, *MYH11*, *MYLK*, *PRKG1*, *SMAD6*, and *SLC2A10* were excluded due to < 5 cases. Limited to the subset of MAC participants with available images (n=240).


478

	<i>z</i>	Odds Ratio	95% CI	<i>P</i>
Age	2.5	1.06	1.01-1.11	0.013
Male sex	0.6	1.53	0.38-6.25	0.55
Missense mutation	2.6	10.8	1.78-65	0.01
MAD	1.8	0.19	0.03-1.18	0.074
MVP or MR	2.8	15.9	2.35-107	0.004

479 Model fit: χ^2 34.5; Nagelkerke R^2 .55; df 5; $P < 0.001$

480

ROC Curve (AUC: 0.889)



481

482

483

484

Figure S6. Logistic regression of composite clinical events (aortic surgery, mitral surgery, aortic dissection, arrhythmia, CHF) for MAC participants with *SMAD3* PV. MVP: any degree of mitral valve prolapse, MR: mild, moderate, or severe mitral regurgitation.